title: Erectile Dysfunction in Systemic Sclerosis.
abstract: Erectile dysfunction (ED) is a major issue in systemic sclerosis (SSc) as it is observed in around 80 to 90 % of men with this connective tissue disease. ED greatly impacts the quality of life and should be actively addressed as a common complication. Whereas ED in the general population is usually associated with risk factors for atherosclerosis as well as cardiovascular disease, the main aetiology of ED in SSc is microangiopathic. In SSc, the blood flow is reduced in the small penile arteries due to corporal fibrosis and myointimal proliferation. There are no data on the prevention of ED in SSc. On-demand phosphodiesterase-5 inhibitors have little effect in improving erectile function, but daily or alternate day regimens of long-acting phosphodiesterase-5 inhibitors provide a measurable, although often limited, benefit. When intracavernous prostaglandin E1 injections are also ineffective, the implantation of a penile prosthesis should be considered as an option.
authors.affiliation: Department of Rheumatology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
authors.forename: Veronika K
authors.initials: VK
authors.lastname: Jaeger
authors.affiliation: Department of Rheumatology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland. ulrich.walker@usb.ch.
authors.forename: Ulrich A
authors.initials: UA
authors.lastname: Walker
mesh_terms: D007172:Erectile Dysfunction / Q000188:drug therapy / Q000209:etiology* / Q000523:psychology; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011788:Quality of Life / Q000523:psychology*; D012595:Scleroderma, Systemic / Q000150:complications* / Q000523:psychology
chemical_list: D010726:Phosphodiesterase Inhibitors
keywords: Causes; Erectile dysfunction; Prevalence; Risk factors; Systemic sclerosis; Treatment